Clinical Trial Detail

NCT ID NCT03711578
Title Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Rhizen Pharmaceuticals SA
Indications

lymphoplasmacytic lymphoma

marginal zone B-cell lymphoma

CLL/SLL

Waldenstroem's macroglobulinemia

follicular lymphoma

Therapies

Tenalisib

Age Groups: adult senior

No variant requirements are available.